| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1545 | |
| Phytochemical name or plant extracts | Ouabain | |
| PMID | 33396341 | |
| Literature evidence | We found that ouabain induces a statistically significant enhancement of GJIC in all of these cancer cell lines, albeit with distinct sensitivity. | |
| IUPAC name | 3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one | |
| Phytochemicals’ class or type of plant extracts | Cardiac glycoside | |
| Source of phytochemicals or plant Extracts | Acokanthera oppositifolia, Acokanthera schimperi | |
| Geographical availability | Acokanthera oppositifolia - Cape Provinces, Kenya, KwaZulu-Natal, Malawi, Mozambique, Northern Provinces, Swaziland, Tanzania, Zambia, Zaïre, Zimbabwe Acokanthera schimperi - Djibouti, Eritrea, Ethiopia, Kenya, Rwanda, Socotra, Somalia, Tanzania, Uganda, Yemen, Zaïre | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Cervico-uterine cancer, Lung cancer, Colon cancer, Pancreatic cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | Ouabain and digoxin activate the cellular proteasome, instigating ER degradation, which causes the inhibition of 17β-estradiol signaling, induces the cell cycle blockade in the G2 phase, and triggers apoptosis. | |
| IC50 | In addition, OU and Digo reduced the proliferation of BC cells in a cell type specific manner, with a calculated IC50 at 5 days for OU of 50 nM, and 60–200 nM for Digo | |
| Potency | NA | |
| Cell line/ mice model | CasKi, SiHa and Hela, MDA-MB-321 and MCF-7, A549, SW480, HPAF-II | |
| Additional information | Induces a statistically significant enhancement of GJIC (gap junctional intercellular communication) in all of these cancer cell lines [(CasKi, SiHa and Hela), breast (MDA-MB-321 and MCF7), lung (A549), colon (SW480) and pancreas (HPAF-II)], albeit with distinct sensitivity. Additionally, gene profiling analysis reveals that these drugs downregulate the expression of genes related to endocrine therapy resistance. Therefore, ouabain and digoxin behave as 'anti-estrogen'-like drugs, and are appealing candidates for the treatment of primary and metastatic BCs. | |
| PubChem ID | 439501 | |
| Additional PMIDs | 33352737 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:76349-1 https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60447729-2 | |
| Safety | NA |